Cubist Systematic Strategies’s Nurix Therapeutics NRIX Stock Holding History

Cubist Systematic Strategies’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$3.03M	Buy	+327,952	New	+$3.41M	0.01%	1303
2025 Q2	–	Sell	-117,615	Closed	-$1.4M	–	3350
2025 Q1	$1.4M	Sell	117,615 -6,410	-5%	-$107K	0.01%	1631
2024 Q4	$2.34M	Buy	+124,025	New	+$2.84M	0.01%	1259
2024 Q2	–	Sell	-36,256	Closed	-$533K	–	3700
2024 Q1	$533K	Buy	+36,256	New	+$390K	﹤0.01%	2568
2023 Q4	–	Sell	-9,830	Closed	-$77.3K	–	3929
2023 Q3	$77.3K	Sell	9,830 -32,722	-77%	-$299K	﹤0.01%	2971
2023 Q2	$425K	Buy	42,552 +17,863	+72%	+$182K	﹤0.01%	2486
2023 Q1	$219K	Buy	+24,689	New	+$257K	﹤0.01%	3183
2022 Q4	–	Sell	-131,919	Closed	-$1.72M	–	4483
2022 Q3	$1.72M	Buy	131,919 +63,235	+92%	+$1M	0.01%	2159
2022 Q2	$870K	Buy	68,684 +9,103	+15%	+$103K	0.01%	2586
2022 Q1	$835K	Buy	59,581 +44,567	+297%	+$791K	0.01%	2179
2021 Q4	$435K	Buy	+15,014	New	+$455K	﹤0.01%	2543
2021 Q3	–	Sell	-12,663	Closed	-$336K	–	3113
2021 Q2	$336K	Buy	12,663 +4,463	+54%	+$131K	﹤0.01%	2261
2021 Q1	$255K	Buy	+8,200	New	+$310K	﹤0.01%	2347

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's NRIX Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Nurix Therapeutics (NRIX) in Q3 2025: 327,952 shares worth $3.03M. The stake represents 0.01% of the portfolio and ranks #1303 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in NRIX as recently as Q1 2025.

Cubist Systematic Strategies first reported a position in NRIX in Q1 2021 and has held it in 13 quarters since. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

Cubist Systematic Strategies held 327,952 shares of Nurix Therapeutics worth $3.03M as of Q3 2025.
Nurix Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
Nurix Therapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1303 holding.
Cubist Systematic Strategies first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 13 quarters since.
173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.